Advanced search
Publication Cover
Clinical Ophthalmology Volume 12, 2018 - Issue
Submit an article Journal homepage
113
Views
11
CrossRef citations to date
0
Altmetric
Original Research

Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial

Kelly K Nichols1 School of Optometry, University of Alabama at Birmingham, Birmingham, AL
,
Edward Holland2 Cincinnati Eye Institute, Edgewood, KY
,
Melissa M Toyos3 Toyos Clinic, Nashville, TN
,
James H Peace4 United Medical Research Institute, Inglewood, CA
,
Parag Majmudar5 Chicago Cornea Consultants, Ltd., Hoffman Estates, IL
,
Aparna Raychaudhuri6 Shire, Lexington, MA, USA
,
Mohamed Hamdani6 Shire, Lexington, MA, USA
,
Monica Roy6 Shire, Lexington, MA, USA
&
Amir Shojaei6 Shire, Lexington, MA, USACorrespondence[email protected]
 show all
Pages 263-270 | Published online: 31 Jan 2018

References

  • CraigJPNicholsKKAkpekEKTFOS DEWS II definition and classification reportOcul Surf201715327628328736335
  • PerezVLPflugfelderSCZhangSShojaeiAHaqueRLifitegrast, a novel integrin antagonist for treatment of dry eye diseaseOcul Surf201614220721526807723
  • SembaCPTorkildsenGLLonsdaleJDA phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eyeAm J Ophthalmol201215361050.e11060.e122330307
  • HollandEJLuchsJKarpeckiPMLifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3)Ophthalmology20171241536028079022
  • SheppardJDTorkildsenGLLonsdaleJDLifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 studyOphthalmology2014121247548324289915
  • TauberJKarpeckiPLatkanyRLifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 studyOphthalmology2015122122423243126365210
  • DonnenfeldEDKarpeckiPMMajmudarPASafety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease: a 1-year, multicenter, randomized, placebo-controlled studyCornea201635674174827055211
  • LeonardiAZafirakisPEfficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked, environmental study of patient preferenceCurr Med Res Opin20042081167117315324519
  • JampelHDSchwartzGFRobinALAbramsDAJohnsonEMillerRBPatient preferences for eye drop characteristics: a willingness-to-pay analysisArch Ophthalmol2003121454054612695251
  • TorkildsenGLOuslerGW3rdGomesPOcular comfort and drying effects of three topical antihistamine/mast cell stabilizers in adults with allergic conjunctivitis: a randomized, double-masked crossover studyClin Ther20083071264127118691985
  • GalorACovingtonDLevittAENeuropathic ocular pain due to dry eye is associated with multiple comorbid chronic pain syndromesJ Pain201617331031826606863
  • BegleyCSimpsonTLiuHQuantitative analysis of tear film fluorescence and discomfort during tear film instability and thinningInvest Ophthalmol Vis Sci20135442645265323532523
  • LiuHBegleyCChenMA link between tear instability and hyperosmolarity in dry eyeInvest Ophthalmol Vis Sci20095083671367919324847
  • KaidoMKawashimaMIshidaRTsubotaKRelationship of corneal pain sensitivity with dry eye symptoms in dry eye with short tear break-up timeInvest Ophthalmol Vis Sci201657391491926943154
  • PuckerADNgSMNicholsJJOver the counter (OTC) artificial tear drops for dry eye syndromeCochrane Database Syst Rev20162CD00972926905373

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.